Lata Vadlamudi

Dr. Lata Vadlamudi

The University of Queensland, Brisbane, Queensland, Australia
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
Sam BerkovicSam Berkovic
Sam Berkovic
LDLeanne M Dibbens
Leanne M Dibbens
AOAlicia Oshlack
Alicia Oshlack
JSJeremy Silver
Jeremy Silver
MKMarina Katerelos
Marina Katerelos
MBMelanie Bahlo
Melanie Bahlo

1 March 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ISIngrid E. Scheffer
Ingrid E. Scheffer
SHSarah E. Heron
Sarah E. Heron
BRBrigid M. Regan
Brigid M. Regan
SMSimone Mandelstam
Simone Mandelstam
DCDouglas E. Crompton
Douglas E. Crompton
LDLeanne M Dibbens
Leanne M Dibbens

26 December 2006 in Neurology
Verified
Journal Article
Closed access
PDF file
FJF. E. Jansen
F. E. Jansen
LSL. G. Sadleir
L. G. Sadleir
LHL. A. Harkin
L. A. Harkin
LVLata Vadlamudi
Lata Vadlamudi
JMJ. M. McMahon
J. M. McMahon
Sam BerkovicSam Berkovic
Sam Berkovic
Establishing an etiologic diagnosis in adults with refractory epilepsy and intellectual disability is challenging. We analyzed the phenotype of 14 adults with severe myoclonic epilepsy of infancy. This phenotype comprised heterogeneous seizure types with nocturnal generalized tonic-clonic seizures predominating, mild to severe intellectual disability, and variable motor abnormalities. The diagnosis was suggested by a characteristic evolution of clinical findings in the first years of life. Ten had mutations in SCN1A and one in GABRG2.

19 September 2017 in Neurology
Verified
Journal Article
Closed access
PDF file
YZYuehua Zhang
Yuehua Zhang
RBRosemary Burgess
Rosemary Burgess
JMJodie P. Malone
Jodie P. Malone
GGGeorgie C. Glubb
Georgie C. Glubb
KHKatherine L. Helbig
Katherine L. Helbig
ISIngrid E. Scheffer
Ingrid E. Scheffer
Objective: Following our original description of generalized epilepsy with febrile seizures plus (GEFS+) in 1997, we analyze the phenotypic spectrum in 409 affected individuals in 60 families (31 new families) and expand the GEFS+ spectrum. Methods: We performed detailed electroclinical phenotyping on all available affected family members. Genetic analysis of known GEFS+ genes was carried out where possible. We compared our phenotypic and genetic data to those published in the literature over the last 19 years. Results: We identified new phenotypes within the GEFS+ spectrum: focal seizures without preceding febrile seizures (16/409 [4%]), classic genetic generalized epilepsies (22/409 [5%]), and afebrile generalized tonic-clonic seizures (9/409 [2%]). Febrile seizures remains the most frequent phenotype in GEFS+ (178/409 [44%]), followed by febrile seizures plus (111/409 [27%]). One third (50/163 [31%]) of GEFS+ families tested have a pathogenic variant in a known GEFS+ gene. Conclusion: As 37/409 (9%) affected individuals have focal epilepsies, we suggest that GEFS+ be renamed genetic epilepsy with febrile seizures plus rather than generalized epilepsy with febrile seizures plus. The phenotypic overlap between GEFS+ and the classic generalized epilepsies is considerably greater than first thought. The clinical and molecular data suggest that the 2 major groups of generalized epilepsies share genetic determinants.

30 September 2010 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
LVLata Vadlamudi
Lata Vadlamudi
LDLeanne M Dibbens
Leanne M Dibbens
KLKate M. Lawrence
Kate M. Lawrence
XIXenia Iona
Xenia Iona
JMJacinta M. McMahon
Jacinta M. McMahon
Sam BerkovicSam Berkovic
Sam Berkovic
De novo mutations are a cause of sporadic disease, but little is known about the developmental timing of such mutations. We studied concordant and discordant monozygous twins with de novo mutations in the sodium channel α1 subunit gene (SCN1A) causing Dravet's syndrome, a severe epileptic encephalopathy. On the basis of our findings and the literature on mosaic cases, we conclude that de novo mutations in SCN1A may occur at any time, from the premorula stage of the embryo (causing disease in the subject) to adulthood (with mutations in the germ-line cells of parents causing disease in offspring).

16 September 2014 in Neurology
Verified
Journal Article
Open access
PDF file
LVLata Vadlamudi
Lata Vadlamudi
RMRoger L. Milne
Roger L. Milne
KLKate Lawrence
Kate Lawrence
SHSarah E. Heron
Sarah E. Heron
JEJazmin Eckhaus
Jazmin Eckhaus
Sam BerkovicSam Berkovic
Sam Berkovic
Objective: Analysis of twins with epilepsy to explore the genetic architecture of specific epilepsies, to evaluate the applicability of the 2010 International League Against Epilepsy (ILAE) organization of epilepsy syndromes, and to integrate molecular genetics with phenotypic analyses. Methods: A total of 558 twin pairs suspected to have epilepsy were ascertained from twin registries (69%) or referral (31%). Casewise concordance estimates were calculated for epilepsy syndromes. Epilepsies were then grouped according to the 2010 ILAE organizational scheme. Molecular genetic information was utilized where applicable. Results: Of 558 twin pairs, 418 had confirmed seizures. A total of 534 twin individuals were affected. There were higher twin concordance estimates for monozygotic (MZ) than for dizygotic (DZ) twins for idiopathic generalized epilepsies (MZ = 0.77; DZ = 0.35), genetic epilepsy with febrile seizures plus (MZ = 0.85; DZ = 0.25), and focal epilepsies (MZ = 0.40; DZ = 0.03). Utilizing the 2010 ILAE scheme, the twin data clearly demonstrated genetic influences in the syndromes designated as genetic. Of the 384 tested twin individuals, 10.9% had mutations of large effect in known epilepsy genes or carried validated susceptibility alleles. Conclusions: Twin studies confirm clear genetic influences for specific epilepsies. Analysis of the twin sample using the 2010 ILAE scheme strongly supported the validity of grouping the “genetic” syndromes together and shows this organizational scheme to be a more flexible and biologically meaningful system than previous classifications. Successful selected molecular testing applied to this cohort is the prelude to future large-scale next-generation sequencing of epilepsy research cohorts. Insights into genetic architecture provided by twin studies provide essential data for optimizing such approaches.